Reaction
Radiation Oesophagitis reporting signals
As of the last recalculation, Radiation Oesophagitis appears in 375 FAERS reports alongside 12 co-occurring drug terms. The strongest observed disproportionality signal is DURVALUMAB (PRR 73.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Durvalumab | 25 | 73.0 | 73.1 |
| Carboplatin | 113 | 70.2 | 70.3 |
| Cisplatin | 77 | 68.6 | 68.7 |
| Granisetron | 12 | 65.6 | 65.6 |
| Granisetron Hydrochloride | 9 | 49.0 | 49.0 |
| Pemetrexed Disodium | 25 | 38.9 | 39.0 |
| Paclitaxel (Aibumin-Bound) | 46 | 35.3 | 35.3 |
| Paclitaxel | 50 | 32.2 | 32.2 |
| Etoposide | 34 | 28.1 | 28.1 |
| Pemetrexed | 10 | 26.6 | 26.6 |
| Erlotinib Hydrochloride | 5 | 22.5 | 22.5 |
| Cetuximab | 10 | 18.2 | 18.2 |